Novo Nordisk A/S — Form 6-K summary
Reporting date: September 28, 2026. The filing reports share repurchases; it does not provide operating results for a financial reporting period.
Share repurchase activity
- Novo Nordisk’s overall repurchase programme is for up to DKK 15 billion over 12 months beginning February 4, 2026.
- A programme initiated May 6, 2026, covers repurchases of B shares of up to DKK 11.2 billion through February 1, 2027.
- From September 21–25, the company repurchased 1,205,000 B shares for approximately DKK 309.9 million. The filing reports cumulative activity under the May programme of 20,620,000 shares and DKK 6,139,842,042, compared with 19,415,000 shares and DKK 5,829,922,946 at the prior announcement.
- Separately, as of September 25, Novo Nordisk reports total repurchases since February 4 of 35,379,179 B shares, at an average DKK 280.95 per share and total transaction value of DKK 9,939,842,031.
- Following the reported transactions, the company held 49,419,876 B shares as treasury shares, or 1.1% of share capital. Total A and B shares, including treasury shares, were 4,465,000,000.
Financial results and outlook
The filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics, and provides no earnings guidance or operating outlook. It describes the repurchase programme and its limits but does not discuss other material risks, contingencies, or unusual items.
Investor verification points
- Confirm the cumulative repurchase figures and programme boundaries: the May programme’s DKK 6.14 billion total is part of the broader programme, whose reported total since February is DKK 9.94 billion.
- Verify the filing’s overall share-count figure of 35,379,179 and average price of DKK 280.95 against the company’s transaction disclosures; the source text contains a spacing irregularity in the share count.
- Check subsequent announcements for further repurchases, changes to the programme, and updated treasury-share holdings.